2. Immunology/Inflammation
  3. BCL6
  4. BCL6-IN-6

BCL6-IN-6 是转录抑制 B 细胞淋巴瘤 6 (BCL6) 的有效抑制剂。BCL6-IN-6 显着阻断 BCL6 与其辅阻遏物的相互作用，并以剂量依赖性方式重新激活 BCL6 靶基因。BCL6-IN-6 具有研究弥漫性大B细胞淋巴瘤 (DLBCL) 的潜力。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BCL6-IN-6 Chemical Structure

BCL6-IN-6 Chemical Structure

CAS No. : 2408882-54-0

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
5 mg ￥2900
In-stock
10 mg ￥4600
In-stock
25 mg 现货 询价
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

BCL6-IN-6 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL)[1].

IC50 & Target

BCL6[1]
细胞效力
(Cellular Effect)
Cell Line Type Value Description References
DOHH-2 IC50
1 μM
Compound: 28
Antiproliferative activity against BCL-6 dependent human DOHH-2 cells by CCK-8 assay
Antiproliferative activity against BCL-6 dependent human DOHH-2 cells by CCK-8 assay
[PMID: 33844535]
DOHH-2 IC50
1.21 μM
Compound: 14j
Antiproliferative activity against human DOHH2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human DOHH2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 31895575]
Farage IC50
1 μM
Compound: 28
Antiproliferative activity against BCL-6 dependent human Farage cells by CCK-8 assay
Antiproliferative activity against BCL-6 dependent human Farage cells by CCK-8 assay
[PMID: 33844535]
Farage IC50
1.26 μM
Compound: 14j
Antiproliferative activity against human Farage cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human Farage cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 31895575]
L02 IC50
13.1 μM
Compound: 14j
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 31895575]
NCM460 IC50
32.4 μM
Compound: 14j
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 31895575]
OCI-Ly7 IC50
1 μM
Compound: 28
Antiproliferative activity against BCL-6 dependent human OCILY7 cells by CCK-8 assay
Antiproliferative activity against BCL-6 dependent human OCILY7 cells by CCK-8 assay
[PMID: 33844535]
OCI-Ly7 IC50
1.62 μM
Compound: 14j
Antiproliferative activity against human OCI-LY7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human OCI-LY7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 31895575]
PNT1A IC50
8.13 μM
Compound: 14j
Cytotoxicity against human PNT1A cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Cytotoxicity against human PNT1A cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 31895575]
SUD4 IC50
0.92 μM
Compound: 14j
Antiproliferative activity against human SUDHL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against human SUDHL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 31895575]
SUD4 IC50
1 μM
Compound: 28
Antiproliferative activity against BCL-6 dependent human SU-DHL-4 cells by CCK-8 assay
Antiproliferative activity against BCL-6 dependent human SU-DHL-4 cells by CCK-8 assay
[PMID: 33844535]
Toledo IC50
3.25 μM
Compound: 14j
Antiproliferative activity against BCL6-negative human Toledo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
Antiproliferative activity against BCL6-negative human Toledo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay
[PMID: 31895575]
Toledo IC50
3.3 μM
Compound: 28
Antiproliferative activity against BCL-6 independent human Toledo cells by CCK-8 assay
Antiproliferative activity against BCL-6 independent human Toledo cells by CCK-8 assay
[PMID: 33844535]
分子量

522.64

Formula

C27H31FN6O2S
CAS 号
性状

固体

颜色

Light yellow to yellow

运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
细胞实验： 

DMSO 中的溶解度 : ≥ 4 mg/mL (7.65 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9134 mL 9.5668 mL 19.1336 mL
5 mM 0.3827 mL 1.9134 mL 3.8267 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
纯度 & 产品资料
参考文献

BCL6-IN-6 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.9134 mL 9.5668 mL 19.1336 mL 47.8341 mL
5 mM 0.3827 mL 1.9134 mL 3.8267 mL 9.5668 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BCL6-IN-62408882-54-0BCL6B-cell lymphoma 6 proteinB-cell lymphoma 5 protein (BCL-5)Zinc finger and BTB domain-containing protein 27Zinc finger protein 51corepressorsDLBCLInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
BCL6-IN-6
目录号：
HY-143653
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z